Interesting comment from Bioshares today on the reason BI pulled the plug.
The reason cited for the discontinuation was because of potentially drug interaction effects which were observed in a small Phase I study only recently completed by Boehringer Ingelheim.
The 10 patient study evaluated the effect of BI 1467335 on monoamine oxidase B (MOA-B) levels, an enzyme involved in dopamine metabolism. Two MOA-B inhibitors, selegiline and rasagiline, are used to treat Parkinson's disease, and the hydrazine class of MOA- B drugs are used as anti-depressants.
Boehringer has decided to discontinue development of BI 1467335 in NASH because of the possibility of side effects occurring in some of the patients taking those drugs, where the numbers of those patients would be significant.
This sort of interaction is going to be a serious problem for all uses of BI 1467335.
PXS Price at posting:
15.0¢ Sentiment: None Disclosure: Not Held
